全球核药龙头大消息

Core Viewpoint - The article highlights the significant milestone achieved by the leading nuclear medicine company, YuanDa Pharmaceutical, in expanding its innovative nuclear drug SIR-Spheres® Yttrium-90 microsphere injection (Yigan Tai®) for the treatment of unresectable hepatocellular carcinoma (HCC), marking a breakthrough in the global nuclear medicine market targeting a potential market size of 10 billion yuan [2][3]. Summary by Sections Product Approval and Clinical Significance - YuanDa Pharmaceutical's SIR-Spheres® Yttrium-90 microsphere injection has received FDA approval for a new indication to treat unresectable HCC, making it the first and only selective internal radiation therapy product approved for both unresectable HCC and colorectal cancer liver metastases [2][4]. - The product utilizes advanced interventional techniques to deliver high-energy beta radiation directly to tumor cells, showcasing its dual advantages as both a radiopharmaceutical and a precise interventional treatment [4]. Market Potential and Growth - The global liver cancer treatment market is projected to reach approximately $9.81 billion by 2030, indicating a substantial opportunity for innovative treatments like Yigan Tai® to address the high unmet medical need in liver cancer therapy [7]. - Since its approval in China, Yigan Tai® has rapidly gained traction, treating nearly 2,000 patients by the end of 2024, with sales revenue expected to reach nearly 500 million HKD, reflecting a year-on-year growth rate exceeding 140% [5]. Industry Position and Future Outlook - YuanDa Pharmaceutical has established a comprehensive nuclear medicine ecosystem through extensive international development and research investments, positioning itself as a leader in the nuclear medicine sector with a robust pipeline of 15 innovative products targeting various cancers [9][10]. - The company aims to enhance its nuclear medicine offerings by integrating diagnostic and therapeutic solutions, thereby solidifying its leadership position in the global nuclear oncology market [10].